可选产品分析
经您允许，我们会使用注重隐私的有限分析来了解哪些研究流程有效。我们不会使用广告跟踪器或会话录制。您可以在偏好设置中更改此选择。请阅读 隐私政策.
Colgate-Palmolive Company's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $68.6B | |
|---|---|---|
| P/E (forward) | 21.0x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $17.42B | $17.97B | $19.46B | $20.10B | $20.38B | +4.0% |
| Gross profit | $10.38B | $10.25B | $11.33B | $12.16B | $12.25B | +4.2% |
| Operating income | $3.33B | $2.89B | $3.98B | $4.27B | $3.31B | -0.2% |
| Net income | $2.17B | $1.79B | $2.30B | $2.89B | $2.13B | -0.4% |
| EPS (diluted) | $2.55 | $2.13 | $2.77 | $3.51 | $2.63 | +0.8% |
| EBITDA | $3.76B | $3.37B | $4.25B | $4.85B | $3.96B | +1.3% |
| R&D | $307.0M | $320.0M | $343.0M | $355.0M | $366.0M | +4.5% |
| SG&A | $6.41B | $6.57B | $7.15B | $7.73B | $7.90B | +5.4% |
Recent company headlines from major financial publishers.
In the base outcome, yielding $74.00 with an estimated probability of 60.0% and an expected return of -14.0%, Colgate-Palmolive delivers steady organic growth across its core franchises. Mass merchant channel inventory stabilizes, and gross profit gains are balanced by necessary advertising reinvestment to maintain defensive market share. However, because $86.06 trades above Fair value of $74.00, the expected return profile remains negative at -14.0%, validating a Reduce recommendation.
In the bull outcome, projected at $101.51 with an estimated probability of 15.0% and an expected return of 18.0%, Colgate-Palmolive accelerates international oral care premiumization while Hill's Pet Nutrition expands veterinary market share globally. Gross margin gains outpace cost inflation, allowing operating margins to surpass historical peaks even after funding strong commercial marketing. This scenario would be disconfirmed if retail partners resist premium shelf allocation or if emerging market currency devaluations erode reported sales gains.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 6.2% | $84.2 | $87.5 | $91.4 | $95.8 | $101 |
| 6.7% | $76.2 | $78.8 | $81.6 | $84.8 | $88.5 |
| 7.2% | $69.9 | $71.8 | $74.0 | $76.4 | $79.1 |
| 7.7% | $64.7 | $66.2 | $67.9 | $69.8 | $71.9 |
| 8.2% | $60.3 | $61.5 | $62.9 | $64.4 | $66.0 |
Upcoming earnings date and setup when available.
每月发布的研究版本所给出的评级。评级比较分析日的价格与公允价值，并不记录判断是否正确。
| 年份 | 1月 | 2月 | 3月 | 4月 | 5月 | 6月 | 7月 | 8月 | 9月 | 10月 | 11月 | 12月 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
